• A case of mantle cell lymphoma with involvement of the entire gastrointestinal tract - Multiple endoscopic findings
• A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS)
• A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
• Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis
• Adult Henoch-Schonlein purpura complicated by IgA-nephritis in a patient with mantle cell lymphoma and Graves disease
• Antibrush Border Antibody Disease: A Case Series
• Aplastic anemia triggered by the Bruton tyrosine kinase inhibitor acalabrutinib in two patients with mantle cell lymphoma - A case report
• Author Correction: SOX11/PRDX2 axis modulates redox homeostasis and chemoresistance in aggressive mantle cell lymphoma
• Autopsy case of cardiac mantle cell lymphoma presenting with recurrent pulmonary tumor embolism after chemotherapy
• Biclonal mantle cell lymphoma
• Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysis
• Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry
• Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi
• CD163+ macrophages in mantle cell lymphoma induce activation of pro-survival pathways and immune suppression
• Central nervous system involvement by non-nodal mantle cell lymphoma masquerading as autoimmune encephalitis versus paraneoplastic syndrome
• Challenges in chimeric antigen receptor-T cell product administration in a high tumor-burden elderly patient with mantle-cell lymphoma
• Characteristics, treatment, and outcomes of mantle cell lymphoma with cutaneous involvement: a decade-long study at MD Anderson cancer center
• Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas
• Clinical and cytological characteristics of serous effusions in 69 cases of lymphoma patients
• Clinical and pathological characteristics of blastoid mantle cell lymphoma: a single institution experience
• Clinical Warburg Effect in a Patient With Mantle Cell Lymphoma: A Case Report
• Clinicopathologic features and outcomes of bilateral lacrimal gland lesions
• Clinicopathological features and prognosis analysis of bone marrow biopsy involvement in 95 cases with mantle cell lymphoma
• Composite mantle cell and Burkitt lymphoma: a rare case report
• Correction: Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma
• Delayed Traumatic Rupture of the Spleen in a Patient with Mantle Cell Non-Hodgkin Lymphoma after an In-Hospital Fall: A Fatal Case
• Diagnosis and treatment of secondary nephrotic syndrome with rash as the first symptom: a case report
• Dialog between mantle cell lymphoma cells and lymphoma-associated macrophages underlies ibrutinib resistance
• Dismantling relapsed/refractory mantle cell lymphoma
• Disruption of cyclin D1 degradation leads to the development of mantle cell lymphoma
• Double trouble: insights from a rare case of extranodal composite lymphoma in an elderly man, with comprehensive literature review
• EBV-Positive Pleomorphic Variant Transformation of CD5-Negative Mantle Cell Lymphoma: A Rare Case Report and Literature Review
• Emerging Role of Functional Magnetic Resonance Spectroscopy (MRS) to Monitor Response to Kinase Inhibitors in Cancer
• Epidemiological, clinical and therapeutic profiles of mantle cell lymphoma cared for in a Moroccan center: a review of 14 cases
• Erratum to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
• Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma
• Exploiting the potential of the ubiquitin-proteasome system in overcoming tyrosine kinase inhibitor resistance in chronic myeloid leukemia
• Gastrointestinal Symptom-Free Multiple Lymphomatous Polyposis: An Atypical Case Presentation of Mantle Cell Lymphoma
• Glofitamab-Associated Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Presenting as Serial Seizures and Responding Positively to Antiseizure Drugs and Anakinra: A Case Report
• Harmonizing efficacy and safety: The potentials of CAR-NK in effectively addressing severe toxicities of CAR-T therapy in mantle cell lymphoma
• Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort
• Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies
• Impact of therapeutic inhibition of oncogenic cell signaling tyrosine kinase on cell metabolism: in vivo-detectable metabolic biomarkers of inhibition
• Importance of long-term follow-up of autologous stem cell transplantation for mantle cell lymphoma
• In-vivo pharmacokinetic study of ibrutinib-loaded nanostructured lipid carriers in rat plasma by sensitive spectrofluorimetric method using harmonized approach of quality by design and white analytical chemistry
• Infections in patients with mantle cell lymphoma
• Insight into Mantle Cell Lymphoma Pathobiology, Diagnosis, and Treatment Using Network-Based and Drug-Repurposing Approaches
• Interference in HbA1c measurement: a case of electropherogram shift due to hyperleukocytosis leading to the discovery of leukemic mantle cell lymphoma
• Intestinal Mantle Cell Lymphoma Complicated With Ileocecal Intussusception in Adults:Report of One Case
• Intrasinusoidal bone marrow involvement in mantle cell lymphoma: a case series with review of the main differential diagnoses
• Is rituximab retro in mantle cell lymphoma?
• Knowledge, skills, and confidence gaps impacting treatment decision making in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma: a quantitative survey study in France, Germany, and the United States
• Laryngotracheal Stenosis Secondary to Mantle Cell Lymphoma
• Late-onset relapsing neurotoxicity after Brexucabtagene autoleucel associated with high chimeric antigen receptor T cells in cerebrospinal fluid
• Mantle Cell Lymphoma and Exaggerated Mosquito Bite Reactions: A New Perspective on Treatment Options
• Mantle cell lymphoma characterized by numerous diffuse polypoid lesions along the entire digestive tract: A case report
• Mantle Cell Lymphoma With Cardiac Involvement Presenting as Complete Heart Block
• Mantle cell lymphoma with IRTA1+ reactive expansion of the marginal zone
• Mantle cell lymphoma with marked plasmacytic differentiation: two contrasting faces
• Mechanisms and management of CAR T toxicity
• MegaAppendix: a rare case of mantle cell lymphoma in an appendix presented as volvulus
• Molecular characterization of a rare case of high-grade B-cell lymphoma with MYC, BCL2, BCL6, and CCND1 rearrangements
• Monitoring of molecular responses to tirabrutinib in a cohort of exceptional responders with relapsed/refractory mantle cell lymphoma
• Non-nodal mantle cell lymphoma mimicking hairy cell leukemia
• Non‑Hodgkin's lymphomas of the lacrimal sac: Current insights and future directions (Review)
• Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe
• Outdoor air pollution and risk of incident adult haematologic cancer subtypes in a large US prospective cohort
• Paraneoplastic glomerulonephritis and kidney infiltration by mantle cell lymphoma: A diagnostic challenge
• PI3K inhibitor idelalisib enhances the anti-tumor effects of CDK4/6 inhibitor palbociclib via PLK1 in B-cell lymphoma
• Pirtobrutinib: a promising therapy for overcoming the resistance of ibrutinib in mantle cell lymphoma
• PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs: approval selpercatinib for solid tumor with RET fusion, gumarontinib for non-small cell lung cancer with MET gene exon 14 skipping mutation, momelotinib for my
• Primary adrenal mantle cell lymphoma mimicking a non-functional retroperitoneal paraganglioma
• Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
• Primary mantle-cell lymphoma of small intestine presenting with intussusceptions: A case report and review of the literature
• Primary ocular adnexal mantle cell lymphoma with distant spread and involvement of the contralateral eye one year later; a case report and literature review
• Prognostic Significance of Progression of Disease within 24 Months in Mantle Cell Lymphoma
• Proteasome inhibition induces apoptosis through simultaneous inactivation of MCL-1/BCL-XL by NOXA independent of CHOP and JNK pathways
• Quantification and Profiling of Early and Late Differentiation Stage T Cells in Mantle Cell Lymphoma Reveals Immunotherapeutic Targets in Subsets of Patients
• Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma
• Rare case of mantle cell lymphoma of the lacrimal sac
• Ready, AIM, stop: ibrutinib plus venetoclax in MCL
• Real-World Evidence of Relapsed/Refractory Mantle Cell Lymphoma Patients and Treatments: A Systematic Review
• Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
• Rituximab maintenance after bendamustine-based treatment for follicular lymphoma and mantle cell lymphoma may exert a negative influence on SARS-CoV-2 infection outcomes
• ROR1-AS1: A Meaningful Long Noncoding RNA in Oncogenesis
• Should We Test for MYC-Rearrangement in Mantle Cell Lymphoma?-An Illustrative Report
• Socioeconomic status, individual behaviors and risk for Lymphomas: a Mendelian randomization study
• SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma
• STAT5B Suppresses Ferroptosis by Promoting DCAF13 Transcription to Regulate p53/xCT Pathway to Promote Mantle Cell Lymphoma Progression
• Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial
• Successful CAR-T cell therapy in a refractory MCL patient with bacterial, fungal and COVID-19 infection: a case report
• Synergistic induction of mitotic pyroptosis and tumor remission by inhibiting proteasome and WEE family kinases
• Targeted Therapies in the Treatment of Mantle Cell Lymphoma
• Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma
• The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma
• The Evolving Role of Bruton's Tyrosine Kinase Inhibitors in B Cell Lymphomas
• The Rules of T-cell Engagement: Current State of CAR T-cells and Bispecific Antibodies in B-cell Lymphomas
• Treatment of Relapsed/Refractory MCL
• Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis
• Viral Hepatitis B Reactivation With Delayed Cholestatic Effect Secondary to Acalabrutinib